The health watchdog MHRA has issued an alert on oral pain relief gels such as Bonjela and Bonjela Cool mint gel for youngsters amid concerns they could develop Reye’s syndrome
The Medicines and Healthcare products Regulatory Agency (MHRA) said that children under 16 should not be given products which contain salicylate salts, as they have the same effect on the body as aspirin and could cause the rare but serious condition, which leads to serious liver and brain damage.
The group said that although no cases have been reported in connection with Bonjela, exposure to the product could increase the risk of developing Reye’s syndrome,
Bonjela Teething Gel, which contains a different formula, is unaffected.
A statement from the MHRA said: ‘This is a precautionary measure only and there are no new safety concerns.
‘The advice is being introduced due to a theoretical risk these products could increase the possibility of a child developing Reye’s syndrome - a rare but serious condition.’
A statement from Reckitt Benckiser, which makes Bonjela, said it had now redesigned the packaging, adding: ‘There have been no confirmed cases of Reye’s Syndrome associated with Bonjela or Bonjela Cool, which remain safe and effective treatments for adults and children 16 years and over.’